Additionally, primaquine efficacy is diminished in individuals who have impaired P450 2D6 (CYP2D6) activity, and around half of malaria patients may have poor or intermediate CYP2D6 metaboliser phenotypes in Thailand.12 The gene discussed is CYP2D6; the disease is malaria.